Suchergebnisse - "Kayser, Sabine"

PubPharm (21)

1

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 2015

von Kayser, S. | Schlenk, R. | Grimwade, D. | +2

2

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 28 January 2015

von Kayser, S.

3

Minimal residual disease-directed therapy in acute myeloid leukemia

enthalten in: Blood | 2015

von Kayser, S. | Schlenk, R. | Grimwade, D. | +2

4

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

enthalten in: Blood | 2014

von Schlenk, R. | Kayser, S. | Bullinger, L. | +23

CommentIn: Blood. 2014 Nov 27;124(23):3341-2. - PMID 25431476

5

Differential impact of allelic ratio and insertion site in FLT3-ITDpositive AML with respect to allogeneic transplantation

enthalten in: Blood | 2014

von Schlenk, R. | Kayser, S. | Bullinger, L. | +22

6

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia : results of the AML Study Group (AMLSG)

enthalten in: Blood | 2013

von Gaidzik, V. | Schlenk, R. | Paschka, P. | +27

7

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

enthalten in: Blood | 2013

von Gaidzik, V. | Schlenk, R. | Paschka, P. | +27

8

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16) : a study of the German-Austrian AML Study Group (AMLSG)

enthalten in: Blood | 2013

von Paschka, P. | Du, J. | Schlenk, R. | +22

9

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

enthalten in: Blood | 2013

von Paschka, P. | Du, J. | Schlenk, R. | +22

10

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

enthalten in: Blood | 2012

von Dolnik, A. | Engelmann, J. | Scharfenberger-Schmeer, M. | +16